Testing AFN50 for hard-to-treat autoimmune diseases
Part of Immune system & allergy clinical trials.
This study tests an experimental drug called AFN50 for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if AFN50 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have one of these autoimmune diseases that hasn't gotten better with standard treatments: lupus, Sjögren's syndrome, myasthenia gravis, systemic sclerosis, inflammatory myopathy, or ANCA vasculitis.
- You have had active disease symptoms for at least 6 months, even while on medications like steroids or immunosuppressants.
- Your organ functions (blood counts, liver, kidneys, heart, lungs) meet certain minimum levels.
- You are not pregnant or breastfeeding, and agree to use birth control for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, STR-P005, for people with autoimmune diseases. It aims to see if the drug is safe and helps by targeting B cells that have a specific marker called CD19.
This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
This trial tests an investigational drug (STR-P004) given by IV to treat kidney diseases caused by the immune system. It aims to see if the drug is safe and tolerable for patients with conditions like lupus nephritis or ANCA vasculitis.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.